News & Comment

We are celebrating 20 years of Nature Reviews Neurology with our November 2025 issue. On reaching this milestone, we have refined and renewed our mission, and we continue to evolve the journal to support the translation of research into real-world benefits.

To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Fernando Cendes, Vice President of the Pan American Federation of Neurology.

To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Elena Moro, President of the European Academy of Neurology.

To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Christopher Chen, President of the Asian and Oceanian Association of Neurology.

To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Natalia S. Rost, President of the American Academy of Neurology.

To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Amina Gargouri and Riadh Gouider, President and Honorary President of the Pan-Arab Union of Neurological Societies.

To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Lawrence Tucker and Augustina Charway-Felli, President and Past President, respectively, of the African Academy of Neurology.

Cerebellar pathology in people with type 1 spinal muscular atrophy (SMA) might contribute to motor and social communication impairments associated with the disease, according to a recent study published in Brain.

Autologous haematopoietic stem cell transplantation (AHSCT) offers effective therapy for people with multiple sclerosis (MS), according to new real-world data.

Glioblastomas can shift glucose metabolism from tricarboxylic acid cycle (TCA) oxidation and neurotransmitter synthesis to growth-promoting pathways, according to new research published in Nature.

A new study presented at the 2025 American Neurological Association Annual Meeting indicates that area postrema syndrome in people with neuromyelitis optica spectrum disorder is related to elevated levels of the gut hormone glucagon-like peptide 1 and its receptor GLP-1R.

A new meta-analysis presented at the 2025 American Neurological Association Annual Meeting shows that initiation of hormone replacement therapy in women soon after the onset of menopause is associated with a reduced risk of Alzheimer disease.

In the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis (MS), dissemination in time is no longer required. This paradigm shift is the result of advances in understanding of MS and the development of other biomarkers, enabling earlier diagnosis and treatment that will ultimately improve long-term outcomes.

The 2024 revisions of the McDonald criteria for multiple sclerosis for the first time permit diagnosis in asymptomatic people with MRI findings suggestive of multiple sclerosis pathology. Although these changes promise opportunities for earlier treatment and improved clinical outcomes, they present a new risk in the form of overdiagnosis.

The 2024 revision of the McDonald criteria for diagnosis of multiple sclerosis marks a substantial departure from previous iterations, establishing a unified framework that integrates presentation, lesion topography and a flexible combination of paraclinical tools. This Clinical Outlook considers the major changes and their clinical implementation, and the implications of the new criteria.

Updates to the McDonald criteria for diagnosis of multiple sclerosis emphasize the value placed on recognizing the earliest manifestations of multiple sclerosis, providing new opportunity to advance understanding of the prodromal phase.

In September 2025, the American Neurological Association (ANA) celebrates its 150th annual meeting (ANA2025), as well as the 75th anniversary of the National Institute of Neurological Disorders and Stroke (NINDS). We asked ANA President M. Elizabeth Ross about the history and achievements of the ANA and about the ANA2025 programme highlights.

Robert Joyce has lived with multiple sclerosis for over 30 years. Here, he highlights the problems with using standard test scores to assess changes in physical and cognitive function and calls for testing to ensure that individual baselines are recorded.

New evidence supports trans-synaptic propagation of tau pathology in the neurodegenerative disease progressive supranuclear palsy.